Meeting
2020 ASCO Virtual Scientific Program
Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients.
Authors
Robert F. Cornell
Vanderbilt University Medical Center, Nashville, TN
Robert F. Cornell , Parameswaran Hari , Stacey Goodman , Luciano J. Costa , Raphael Fraser , Noel Estrada-Merly , Shaji Kumar , Muzaffar H. Qazilbash , Anita D'Souza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for Plasma Cell Disorders
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8515)
DOI
10.1200/JCO.2020.38.15_suppl.8515
Abstract #
8515
Poster Bd #
415
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Will adding alkylating agent to bortezomib improve survival of newly diagnosed AL amyloidosis patients?
First Author: Yumeng Zhang
Poster
2018 ASCO Annual Meeting
Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.
First Author: Ray Comenzo
Poster
2015 ASCO Annual Meeting
Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL).
First Author: Morie A. Gertz
Poster
2020 ASCO Virtual Scientific Program
Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.
First Author: Efstathios Kastritis